BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36485069)

  • 1. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
    Wu X; Shen S; Qin J; Fei W; Fan F; Gu J; Shen T; Zhang T; Cheng X
    BJOG; 2022 Nov; 129 Suppl 2(Suppl 2):40-49. PubMed ID: 36485069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and Prognostic Significance of Ferroptosis-related Proteins SLC7A11 and GPX4 in Renal Cell Carcinoma.
    Ren Z; Zhang X; Han J
    Protein Pept Lett; 2023; 30(10):868-876. PubMed ID: 37807410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
    Lim W; Kim HS; Jeong W; Ahn SE; Kim J; Kim YB; Kim MA; Kim MK; Chung HH; Song YS; Bazer FW; Han JY; Song G
    PLoS One; 2012; 7(11):e49869. PubMed ID: 23185467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
    Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
    Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
    Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
    Pan ZM; Tan FC; Chen CX; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis.
    Liu W; Zhou Y; Duan W; Song J; Wei S; Xia S; Wang Y; Du X; Li E; Ren C; Wang W; Zhan Q; Wang Q
    Clin Transl Med; 2021 Sep; 11(9):e517. PubMed ID: 34586745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
    Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
    J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of lnc-MyD88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
    Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
    Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.